logo

Esperion Therapeutics (ESPR)



Trade ESPR now with
  Date
  Headline
6/22/2020 7:10:50 AM Esperion Completes Amendment To EU Commercial Collaboration Agreement With Daiichi Sankyo Europe
6/14/2020 12:07:21 PM Esperion Announces Pooled Analysis From Phase 3 LDL-C Lowering Clinical Development Program Of NEXLETOL Tablets
6/4/2020 7:10:10 AM Esperion Reports Commercial Availability Of NEXLIZET Tablets
4/20/2020 7:26:21 AM Esperion Agrees With Otsuka Pharma For Commercialization Of NEXLETOL And NEXLIZET Tablets In Japan
4/6/2020 7:14:25 AM Esperion Says European Commission Approves NUSTENDI Tablet For Hypercholesterolemia And Dyslipidemia
3/18/2020 7:31:58 AM Esperion Names Alan Fuhrman To Board Of Directors
9/5/2019 7:49:06 AM Esperion Completes Patient Enrollment In Global CLEAR Cardiovascular Outcomes Trial For Bempedoic Acid
1/4/2019 7:04:29 AM Esperion Announces Agreement With Daiichi Sankyo Europe To Commercialize Bempedoic Acid In Europe
8/27/2018 7:04:30 AM Esperion Announces Positive Top-Line Results From Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study
8/25/2018 7:15:33 AM Esperion Announces Late-Breaking Oral Presentation Of Final Results Of Phase 3 Long-Term Safety Study Of Bempedoic Acid